DB01276ApprovedInvestigationalProtein Based TherapiesBlood Glucose Lowering AgentsGLP-1 AgonistsIncretin Mimetics
Exenatide is a GLP-1 agonist used in the management of type 2 diabetes mellitus. Exenatide is a glucagon-like peptide-1 (GLP-1) analog.
- Mechanism
- Curator reviewed
Exenatide is a human glucacon-like peptide-1(GLP-1) receptor agonist. By activating this receptor, insulin secretion is increased and glucagon secretion is decreased in a glucose dependant manner. Exenatide also slows gastric emptying and decreases food intake. These effects work synergistically to improve glycemic control by reducing the likelihood of hyper and hypoglycemia.
- Primary indication
- Exenatide is indicated as an adjunct to diet and exercise to improve glycemic control in patients with type 2 diabetes.Curator reviewed · 2 structured indications
- Formula / weight
- C184H282N50O60S · 4186.6 Da
- First approval
- Canada, 2014 · United States, 2005
- Also known as
- Exenatide synthetic · Exendin 4 · Exendin-4 · Synthetic exendin-4
- Code names
- AC-002993 · AC-2993 · AC-2993A · AC-2993LAR · DA-3091 · ITCA-650 · LY-2148568
- Brand names
Resolves to
Clinical / RWD
Targets
What you can answer from here — as of July 17, 2026
1Protein targetEach mapped to UniProt, with action and pharmacological actionListed above
Which drugs share a target with Exenatide, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account